SCHEMBL968181

SCHEMBL968181

CN1CCC(c2ncc3c4c(sc3n2)CN(CC(=O)N2CCN(C3CCC3)CC2)CC4)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.37
F10 P00742 4/20 0.36
TMEM97 Q5BJF2 2/20 0.35
KCNH2 Q12809 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
HPGD P15428 2/20 0.33
F2 P00734 2/20 0.33
HIF1A Q16665 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MAPT P10636 1/20 0.32
JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969371 0.94 PARP1 (0.40) PARP1TMEM97KCNH2SIGMAR1ALDH1A1
SCHEMBL969349 0.94 PARP1 (0.40) PARP1TMEM97KCNH2SIGMAR1ALDH1A1
SCHEMBL969215 0.93 PARP1 (0.41) PARP1TMEM97KCNH2SIGMAR1ALDH1A1
SCHEMBL968124 0.93 PARP1 (0.40) PARP1TMEM97KCNH2SIGMAR1ALDH1A1
SCHEMBL971614 0.90 TMEM97 (0.38) PARP1TMEM97KCNH2SIGMAR1ALDH1A1
SCHEMBL966767 0.86 PARP1 (0.40) PARP1TMEM97SIGMAR1ALDH1A1KDM4E
SCHEMBL968565 0.85 PARP1 (0.39) PARP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL971597 0.85 PARP1 (0.39) PARP1TMEM97KCNH2ALDH1A1KDM4E
SCHEMBL970417 0.85 PARP1 (0.40) PARP1TMEM97SIGMAR1ALDH1A1KDM4E
SCHEMBL971385 0.84 PARP1 (0.39) PARP1F10ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885F10 3764/4885TMEM97 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.